Literature DB >> 29536273

A Simple Approach to Determine a Curve Fitting Model with a Correct Weighting Function for Calibration Curves in Quantitative Ligand Binding Assays.

Yuhong Xiang1, Jean Donley1, Elena Seletskaia1, Sonal Shingare2, John Kamerud1, Boris Gorovits3.   

Abstract

In ligand binding assays (LBA), the concentration to response data is a nonlinear relationship driven by the law of mass action. Four parameter logistic (4PL) and five parameter logistic (5PL) curve fitting models are two widely accepted and validated models for LBA calibration curve data. Selection of the appropriate regression model and weighting function are key components of LBA development. Assessment of selected model and weighting function should be performed during assay development and confirmed later during validation. There has been limited published work on practical approaches to determining an appropriate weighting function and selection of a regression model for ligand binding assays. Herein, a structured scheme is presented to determine both. By applying commonly available software, assay performance data were analyzed to determine weighting functions and associated choice of a curve fitting model in three presented case studies. As a result, assay ranges of quantification were improved by reducing lower limit of quantification (from 1.00 to 0.317 ng/mL in one case study and from 2.06 to 1.37 ng/mL in another) or extending both low and upper limits of quantification(e.g., 1.04 to 48.3 ng/mL improved to 0.602 to 145 ng/mL). In addition, assay calibration curve performance demonstrated improved assay accuracy (%RE) and precision (%CV). Recommendations on decision flow when determining appropriate weighting function and curve fit model are presented.

Keywords:  LBA; calibration curve; heteroscedasticity; pharmacokinetic assay; weighting function

Mesh:

Substances:

Year:  2018        PMID: 29536273     DOI: 10.1208/s12248-018-0208-7

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  7 in total

1.  Implications for clinical pharmacodynamic studies of the statistical characterization of an in vitro antiproliferation assay.

Authors:  L M Levasseur; H Faessel; H K Slocum; W R Greco
Journal:  J Pharmacokinet Biopharm       Date:  1998-12

2.  Validation of immunoassays for bioanalysis: a pharmaceutical industry perspective.

Authors:  J W Findlay; W C Smith; J W Lee; G D Nordblom; I Das; B S DeSilva; M N Khan; R R Bowsher
Journal:  J Pharm Biomed Anal       Date:  2000-01       Impact factor: 3.935

3.  The problem of overfitting.

Authors:  Douglas M Hawkins
Journal:  J Chem Inf Comput Sci       Date:  2004 Jan-Feb

4.  The five-parameter logistic: a characterization and comparison with the four-parameter logistic.

Authors:  Paul G Gottschalk; John R Dunn
Journal:  Anal Biochem       Date:  2005-08-01       Impact factor: 3.365

5.  Appropriate calibration curve fitting in ligand binding assays.

Authors:  John W A Findlay; Robert F Dillard
Journal:  AAPS J       Date:  2007-06-29       Impact factor: 4.009

6.  Guidelines for immunoassay data processing.

Authors:  R A Dudley; P Edwards; R P Ekins; D J Finney; I G McKenzie; G M Raab; D Rodbard; R P Rodgers
Journal:  Clin Chem       Date:  1985-08       Impact factor: 8.327

7.  Calibration Curves in Quantitative Ligand Binding Assays: Recommendations and Best Practices for Preparation, Design, and Editing of Calibration Curves.

Authors:  Mitra Azadeh; Boris Gorovits; John Kamerud; Stephen MacMannis; Afshin Safavi; Jeffrey Sailstad; Perceval Sondag
Journal:  AAPS J       Date:  2017-12-27       Impact factor: 4.009

  7 in total
  4 in total

1.  Resistance Exercise Training Improves Metabolic and Inflammatory Control in Adipose and Muscle Tissues in Mice Fed a High-Fat Diet.

Authors:  Pauline S Effting; Anand Thirupathi; Alexandre P Müller; Bárbara C Pereira; Diane M Sepa-Kishi; Luis F B Marqueze; Franciane T F Vasconcellos; Renata T Nesi; Talita C B Pereira; Luiza W Kist; Maurício R Bogo; Rolando B Ceddia; Ricardo A Pinho
Journal:  Nutrients       Date:  2022-05-24       Impact factor: 6.706

2.  Development of a sensitive trial-ready poly(GP) CSF biomarker assay for C9orf72-associated frontotemporal dementia and amyotrophic lateral sclerosis.

Authors:  Katherine M Wilson; Eszter Katona; Idoia Glaria; Mireia Carcolé; Imogen J Swift; Aitana Sogorb-Esteve; Carolin Heller; Arabella Bouzigues; Amanda J Heslegrave; Ashvini Keshavan; Kathryn Knowles; Saurabh Patil; Susovan Mohapatra; Yuanjing Liu; Jaya Goyal; Raquel Sanchez-Valle; Robert Jr Laforce; Matthis Synofzik; James B Rowe; Elizabeth Finger; Rik Vandenberghe; Christopher R Butler; Alexander Gerhard; John C Van Swieten; Harro Seelaar; Barbara Borroni; Daniela Galimberti; Alexandre de Mendonça; Mario Masellis; M Carmela Tartaglia; Markus Otto; Caroline Graff; Simon Ducharme; Jonathan M Schott; Andrea Malaspina; Henrik Zetterberg; Ramakrishna Boyanapalli; Jonathan D Rohrer; Adrian M Isaacs
Journal:  J Neurol Neurosurg Psychiatry       Date:  2022-04-04       Impact factor: 13.654

3.  Gender Differences in Developing Biomarker-Based Major Depressive Disorder Diagnostics.

Authors:  Mike C Jentsch; Huibert Burger; Marjolein B M Meddens; Lian Beijers; Edwin R van den Heuvel; Marcus J M Meddens; Robert A Schoevers
Journal:  Int J Mol Sci       Date:  2020-04-25       Impact factor: 5.923

4.  Combining Electrochemiluminescence Detection with Aptamer-Gated Indicator Releasing Mesoporous Nanoparticles Enables ppt Sensitivity for Strip-Based Rapid Tests.

Authors:  Estela Climent; Knut Rurack
Journal:  Angew Chem Int Ed Engl       Date:  2021-11-09       Impact factor: 16.823

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.